RAPT Therapeutics, Inc. RAPT
Updated: 17 Jun 2026
No signal published yet
We already track RAPT Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow RAPT Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow RAPT Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In the first half of 2024, the FDA placed a clinical hold on trials for the lead candidate zelnecirat following a report of a serious adverse event involving liver injury. Consequently, the company implemented a workforce reduction of approximately 40 percent to preserve capital while investigating the event and coordinating with regulatory authorities.
What Firelda Watch includes for RAPT Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow RAPT Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow RAPT Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more